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Abstract 
Prazosin is one of the alphaone adrenoreceptor blocker used in hypertension, benign prostatic hyperplasia, prostate 
cancer etc. The alpha blockers are relatively inexpensive and exert their effects quickly and Prazosin is the most commonly 
used alpha blocker. This review highlights various analytical methods for the determination of Prazosin hydrochloride in 
different matrices. Analytical methods reported are classified into four categories viz; spectrophotometry, chromatography, 
pharmacopoeial and other methods. The methods were described in terms of sensitivity (LOD & LOQ), linear range, 
principle and its applicability. This review also briefly highlights pharmacology of prazosin. This review is helpful for the 
researchers and scientists studying Prazosin hydrochloride in its analytical and pharmacological aspect. 
Keywords: Prazosin, Hypertension, Benign Prostatic Hyperplasia, Analytical methods, Spectrophotometry, 
Chromatography. 
 
1. Introduction 
Prazosin Hydrochloride [CAS number 19237-84-
4], [4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-
piperazinyl]-2-furanylmethanone, 1-(4-amino-6,7-
dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) 
piperazine and 2-[4-(2-furoyl)piperazin-1-yl]-4-amino-6,7-
dimethoxy quinazoline furazosin [1] a quinazoline 
derivative, is a peripheral vasodilator used in the treatment 
of arterial hypertension and congestive heart failure (CHF). 
Prazosin is extensively metabolised by the liver and has 
high first-pass metabolism and low oral bioavailability. In 
normal healthy volunteers, the time of peak concentration 
occurs between 1 and 3 hours after oral administration, 
with wide interindividual variations. The extent of oral 
absorption seems to be similar for different pharmaceutical 
forms and is not influenced by the presence of food in the 
digestive tract. Oral bioavailability of prazosin ranges from 
43.5 to 69.3% (mean 56.9%). Prazosin is highly (92 to 
97%) bound to human plasma proteins (albumin and alpha 
1-acid glycoprotein) and the extent of binding is 
independent of the plasma concentration of the drug in the 
range of 20 to 150 ng/ml [2].  
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Figure 1: Structure of Prazosin Hydrochloride and impurities: (1) Prazosin Hydrochloride (2) Ar: 2-chloro-6,7-
dimethoxyquinazolin-4-amine, (3) 1,4-bis(furan-2-ylcarbonyl)piperazine, (4) 6,7-dimethoxy-2-(piperazin-1-
yl)quinazolin-4-amine, (5) 1-(furan-2-ylcarbonyl)piperazine, (6) 2,2′-(piperazin-1,4-diyl)bis(6,7-
dimethoxyquinazolin-4-amine) 
 
Selective α1-blockers (Prazosin and doxazosin) 
causes vasodilation. They are also used for benign prostatic 
hyperplasia (relaxation of urinary tract smooth muscle), 
congestive heart failure and Raynaud’s disease. All α-
blockers should be titrated carefully as first-dose 
hypotension can be severe. They have additional 
favourable metabolic effects on lipid and glucose 
metabolism [3]. 
The quinazoline-based α1-blockers have been 
shown to have antitumor efficacy against prostate cancer 
cells via their potency to induce apoptosis and anoikis via 
an α1-adrenoceptor- independent mechanism [4]. Prazosin 
is a potential anticancer agent that induces apoptotic 
signaling cascades in a sequential manner [5].  
Prazosin was the next selective (after Phenoxybenzamine) 
alpha-1-blocker used to manage benign prostatic 
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hyperplasia (BPH), at which time it was already being used 
for treating hypertension. Prazosin must be given three 
times per day to be effective for BPH. The prostatic-
specific subtype is alpha-a, an adrenergic receptor that 
constitutes 70% of all prostatic alpha-1 receptors. Since 
alpha-1 receptors are also present at various nonprostatic 
smooth muscles, they are not entirely uroselective. 
Blockade of these receptors causes few additional 
unwanted systemic side effects [6]. The first-dose effect 
(profound postural hypotension and reflex tachycardia) is a 
well-recognized complication of the first dose of prazosin 
and related agents. This phenomenon is dose-related and 
can usually be avoided by using a low initial dosage taken 
at bedtime [7]. It has been suggested that the high affinity 
for the αl-adrenoceptor is due to 2,4-diamino-6,7- 
dimethoxyquinazolinium nucleus [8]. 
In recent review article, Prazosin was suggested as 
well-tolerated generically available medication that has a 
small but positive evidence base for the treatment of 
posttraumatic stress disorder associated nightmares [9]. 
Prazosin is synthesized from 2-amino-4,5-
dimethoxybenzoic acid, which upon reaction with sodium 
cyanate undergoes heterocyclation into 2,4-dihydroxy-6,7-
dimethoxyquinazoline. Substituting hydroxyl groups of this 
compound with chlorine atoms by reaction with thionyl 
chloride, or a mixture of phosphorous oxychloride with 
phosphorous pentachloride gives 2,4-dichloro-6,7-
dimethoxyquinazoline. Upon subsequent reaction with 
ammonia, the chlorine atom at C4 of the pyrimidine ring is 
replaced with an amino group, which leads to the formation 
of 4-amino-2-chloro-6,7-dimethoxyquinazoline. 
Introducing this into a reaction with 1-(2-furoyl)piperazine 
gives prazosin [10]. 
Prazosin are usually prepared as solid-state forms of 
prazosin hydrochloride, five crystalline polymorphic 
modifications of which are claimed, namely, forms α, β, γ, 
δ, and ε [11]. The alpha form is reproducibly manufactured 
and has valuable advantages over the other polymorphic 
forms due to ease of handling, storage, stability and 
formulating. This alpha form was used in clinical trials to 
khow efficacy of the drug. Prazosin hydrochloride is a 
white to off-white, crystalline, odorless powder [12]. Its 
chemical formula is C19H21N5O4, molecular weight is 
383.41 and melting point is 278-280 °C [1]. 
 
2. Analytical methods 
2.1 Spectrophotometry methods 
Spectrophotometry methods are among the oldest 
methods of analytical chemistry. Spectrophotometric 
methods of identification and determination of substances 
are based on the existence of relationship between the 
position and the intensity of absorption bands of 
electromagnetic radiations, on the one hand, and the 
molecular structure on the other [13]. 
In this paper, twenty one different 
spectrophotometry methods are described. The summary of 
these methods are presented under Table 1. Methods 
available in the current literature are described in terms of 
principle, linear range, limit of detection (LOD), limit of 
quantitation (LOQ) and applicability. It is clear from Table 
1 that spectrofluorimetry methods are more sensitive 
methods as compared to direct and simple 
spectrophotometry methods. Flow injection analysis by 
using spectrofluorimetry has additional advantage over 
other methods of determining many samples in a short 
period of time.  
Table 1: Summary of various spectrophotometry methods for Prazosin HCl determination 
Principle Wavelength 
Linear 
Range 
LOD LOQ Application Ref. 
Ion pair formation with bromocresol purple 410 nm 2-10 μg/ml - - Tablets 14 
Reaction with mercurochrome 542 nm 5-10 μg/ml - - Tablets 
Fluoremetry: with mercurochrome in aqueous neutral 
buffered solution. 
λex = 295, λem = 530 
 
0.05-
0.2μg/ml 
- - Tablets 
Dissolved in Britton–Robinson buffer at pH 1.8. 317, 329 and 341 
nm. 
1.0×10-7 and 
5.0×10-5 M 
0.9×10 -
7 M 
1×10 -7 
M 
Tablets 15 
Coloured derivative between the drug and 1,2-
naphthoquinone-4- sulphonic acid sodium salt (NQS). 
The reaction proceeds quantitatively at pH 4.5 and 
70°C for 40 min and extracted with chloroform: n-
butanol (3:1). 
400 nm 6-30 μg /mL - 
 
40 
µg/ml 
 
Tablets  16 
Second-derivative in 0.2 N methanolic hydrochloric 
acid 
Positive peak at 356 
nm, negative peak at 
346 nm 
l-20 μg /mL - - Polythiazide/prazosin 
mixtures in 
tablets 
17 
Reaction with 2,3,-dichloro-5,6-dicyano-p-
benzoquinone (DDQ) in acetonitrile. 
460 nm 5–60 μg /mL - - Tablets 18 
Reaction with bromophenol blue (BPB) in CHCl3 410 nm 2–18 μg /mL - - Tablets 
Treating with excess N-bromosuccinimide (NBS) and 
determining the unconsumed NBS with p-,N-methyl 
aminoophenol sulphate (meto])-sulphanilamide (SA) 
reagent 
 520 nm 1- 10.0 μg 
/mL 
  Tablets 19 
Treating with 3-methyl-2-benzothiazolinone 
hydrazone hydrochloride (MBTH) in the presence of 
ceric ammonium sulphate (CAS) 
 620 nm 2.5-25 μg 
/mL 
  Tablets 
Treating with acidic dyes such as orange-II (O-11) 
and alizarin violet 3B 
490 and 570 nm 1- 17.5 and 
2.5-30.0 μg 
/mL resp. 
  Tablets 
Dilutions prepared in methanol 246nm 5-80 μg /mL 1 μg 
/mL 
2.2 μg 
/mL 
API and tablet 20 
Diazotization with sodium nitrite and hydrochloric 
acid and reaction with β naphthol 
480 nm 40-225 μg 
/mL 
1.23 μg 
/mL 
4.1 μg 
/mL 
Tablets 21 
Complex with rose Bengal (RB) 572 nm 2.5 - 25 μg 
/mL 
0.89 μg 
/mL 
0.5-8 
μg /mL 
Tablets 22 
Fluorimetry:  Dilutions prepared with Clark and Lubs 
buffer solution pH 5.5 
λem 388 nm using λex 
340 nm.  
0.05– 1.4 μg 
/mL 
0.019 
μg /mL 
0.182 
μg /mL  
Tablets 
Fluorimetry:  Dilutions prepared with Clark and Lubs 
buffer solution pH 5.5. The difference in the 
fluorescence intensity (ΔF) was plotted vs. the final 
concentration of the drug (μg/mL) to get the 
calibration curve 
577 nm after 
excitation at 483 nm. 
0.5 –8 μg 
/mL 
0.006 
μg /mL 
0.55 
μg /mL 
Tablets 
Drug extracted from blood by ethyl acetate after 
alkalinization of the plasma with NaOH and then 
extracted back from the ethyl acetate into 0.1 N HC1 
and estimated by spectrofluorimetry.  
λeex 330 nm, λeem 390 
nm 
 
- - - plasma prazosin levels 23 
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Fluorimetry: Bovine serum albumin (BSA) and Tris-
HCl buffer (pH 7.4) used to prepare dilution 
λex 280 nm with λem 
recorded between 
300–520nm. 
0 to 1.58×10-
7 mol L-1 
- -  Interaction  studies 
with BSA 
24 
Spectrofluorimetry λex = 244 nm (λem ≥ 
389 nm) 
 
0.02–2.43 
mg l−1 
0.007 
mg l−1 
- Tablets 25 
Spectrofluorimetry, 
Flow injection analysis enhancement of the native 
fluorescence 
in the presence of sodium dodecyl sulfate (SDS)  
λex = 250 
and λem = 390 
20–400 ng 
ml−1 
326.5 
ng ml−1 
13.8 
ng ml−1 
Pure and Tablets  26 
Reaction with 1,2- 
naphthoquinone-4-sulfonic acid sodium salt (NQS). 
The reaction proceeds 
quantitatively at pH = 4.5 and 70 °C in 40 min. After 
the extraction of the 
derivative with chloroform: n-butanol (3:1).  
400 nm 40-200 
μg/mL 
- - Tablets 27 
 
2.2 Chromatography methods 
High-performance liquid chromatography (HPLC) 
was introduced to pharmaceutical analysis not long after its 
discovery in the late 1960s. By now it has developed into a 
generally applicable analytical method providing rapid and 
versatile separation possibilities that meet the increasing 
requirements for purity testing of bulk pharmaceuticals and 
pharmaceutical products [28].  
The summary of chromatography methods for the 
determination of Prazosin is provided under Table 2. 
Different official methods are described in Table 3. HPLC 
coupled with different types of detectors such as UV, MS, 
RLS, Fluorosence and Electrochemical detectors were used 
for analysis of prazosin in different matrices. 
The modern HPTLC technique, combined with 
automated sample application and densitometric scanning, 
is sensitive and completely reliable, suitable for use in 
qualitative and quantitative analysis. HPTLC is a valuable 
tool for reliable identification because it can provide 
chromatographic fingerprints that can be visualized and 
stored as electronic images [28]. Three different methods 
are also described under Table 2. 
Table 2: Summary of different chromatography methods for the determination of Prazosin HCl in different 
matrices 
Method Chromatographic condition 
Linear 
range 
LOD LOQ Application Ref. 
HPLC-F μBondapak CN particle size 10 μm, 30 cm × 3-9 mm 
column. Mobile phase: acetonitrile-water:acetic acid 
(50:47:3) flow-rate 2.2 ml/min, λex = 248 nm, λem 389. 
1-15 ng/ml - - Human Plasma 29 
HPLC- 
Electrochemical 
Detection 
  
ODS Hypersil HPLC column (150 x 4.6 mm). Mobile 
phase consisting of 0.05 M NazHPO4-acetonitrile (60:40), 
pH 8.4. Flow rate 1.0 ml/min. Potential of channel 2 was 
kept at + 0.00 mV and the guard cell had a potential of + 
300 mV. 
5 ng/ml to 
250 ng/ml 
2.5 
ng/ml 
- Serum samples 30 
HPLC-F Column: 10mm × 25cm, Partisil 10-SCX cation-
exchanger. Mobile phase: 14.7% acetonitrile, 83.4% 
deionized water, 0.5% diethylamine and 1.3% 
orthophosphoric acid. The flow rate was 2 ml/min. λex = 
246 nm, λem = 370 nm.  
Prazosin: 
1-60 
ng/ml, 
metabolite 
1-120 
ng/ml 
0.1-0.2 
ng/ml for 
both 
- prazosin and its 
metabolite 
in serum, urine and 
saliva 
31 
HPLC-F Varian Micro-Pak MCH-10 (monomeric C18 bonded) 
reversed phase column (25 cm x 2.0 mm I.D.). One pump 
contained a 0.01 M pentane sodium sulfate in water 
adjusted to pH 3.4 with glacial acetic acid (solvent A). The 
other pump contained the same concentrations of pentane 
sodium sulfate and acetic acid as solvent A in methanol 
(solvent B). An isocratic mixture of 49 % solvent B and 
51% solvent A was used with daily minor adjustments in 
solvent composition (1-2 %) to maintain optimum baseline 
separation of prazosin and the internal standard. The flow-
rate = 40 ml/h. λem = 390 nm, λex = 246 nm 
0.2 ng to 
50 ng/ml  
0.2 ng/ml 
in whole 
blood and 
0.5 ng/ml 
in plasma 
- Pharmacokinetic 
studies 
32 
HPLC-F Column: μBondapak Cl8 reversed-phase column (30 cm × 
3.9 mm ID, 10 μm particle size), λex = 340 nm, λem = 384 
nm 
 
l-164 
ng/ml. 
0.1 ng/ml 
in 
plasma, 
urine and 
whole 
blood. 
- Pharmacokinetic 
studies 
33 
HPLC-F ODS column (25 cm x 4.6 mm i.d.) of 5μm particle size 
(Finepak SIL C18-5; Jasco). The ODS guard column had 
dimensions 5cmx4.6 mm i.d. (Finepak SIL C18-5). Mobile 
phase: methanol-water- PIC B-5 (456:24:1,v/v). Flow rate 
of 1.0 ml min. λex 340 and λem 405 nm. 
0.1 to 30 
pmol/ml 
0.2 
pmol/ml 
0.4 pmol 
m1-1 
Plasma 
determination 
34 
HPLC-UV Nuclosil 100-10, C-18 column (250×4.6mm, 10 micron) 
using methanol:water:acetonitrile (60:45:5 v/v, pH 3.83) as 
the mobile phase at a flow rate of 1mL min-1 effluents λ = 
240 nm. 
2.5 to 50 
μg ml-1 
0.0315 μg 
ml-1 
(Bulk) 
0.0174 
(Serum) 
0.0953 
μg ml-1 
(Bulk) 
0.0527 
(Serum) 
Human Serum 35 
HPLC-UV Column: Nuclosil, C18 (250×4.6 mm, 10 μm), mobile 
phase 75:25 v/v acetonitrile:water having pH 3.20 adjusted 
with glacial acetic acid. Flow rate of 1.5 ml min−1 using 
gradient elution through prepacked. λ = 250 nm. 
1.0-10 μg 
ml−1 
3.3 ng 
ml−1 
(Bulk) 
9.8 ng 
ml−1  
(Serum)  
2.2 ng 
ml−1 
(Bulk) 
and 6.1 
ng ml 
(Serum) 
Pharmaceutical 
formulation, human 
serum, Drug–metal 
interaction studies 
36 
(LC‑ESI‑TOF/MS Thermo Scientific C18 (250 mm × 2.1 mm, i.d.: 5 μm) 
column. Dilutions of this mixture were prepared in 0.1% 
formic acid in (Methanol-water (10:90, v/v)). Mobile 
phase: (A) 0.1% FA in water and (B) Acetonitrile-
Methanol (3:1, v/v) at 0.3 ml min–1. The elution started at 
5% B and was then linearly increased to 60% B over 3 
min, further increased to 97% B over 3 min and then kept 
isocratic for 5 min. 
1.5-150 
μgl–1 
- 33 ng/ml Analysis in Tangkas 
River-Malaysia 
37 
HPLC-F Cosmosil column, 5C18-MS II (150 × 4.6 mm, 5 μm i.d.). 
Security guard cartridge (C18) (4 mm × 3 mm, i.d.) was 
0.5-20 ng 
ml-1 
0.16-0.71 
ng ml-1 
0.53-2.14 
ng ml-1 
Rabbit plasma 38 
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from Phenomenex. Mobile phase containing acetonitrile 
and 20 mM phosphate buffer (pH 6.3) (60:40, v/v) 
containing 25 mM SDS (Sodium dodecyl sulfate), λem = 
389 nm, λex =250 nm. 
HPLC-UV Column: Nucleosil C18 (250mm x 4.6 mm, 10μm), mobile 
phase: methanol: acetonitrile (85:15 v/v pH 3.0 adjusted 
by phosphoric acid 85 %). Flow rate was 1.0 mL min-1. λ = 
240 nm. 
2.5-1000 
μg ml-1 
4.0 ng 
mL-1   
12.1 ng 
mL-1 
Bulk, formulations 
and human serum 
39 
HPLC-RLS Gemini 5μ C18 reversed phase column (250 mm × 4.6 
mm; 4 μm). The mobile phase consisted of methanol (B) 
and ammonium acetate–formic acid buffer solution (25 
mM; pH = 3.0) (D). The gradient elution performed was: 
0–9 min hold at 18% B, 82% D; 9–20 min, turn from 
initial conditions to 30% B, 70% D. The RLS signal was 
monitored at λex = λem = 354 nm. 
0.075–3.0 
μg l-1 
0.065 μg 
l-1 
- Separation of 
Prazosin, doxazosin 
and terazosin 
40 
HPTLC Silica gel G 60 F254 plates (10 cm w×10 cm h) with 250 
mm thickness. Mobile phase composed of acetonitrile and 
phosphate buffer (0.02 mole=L) adjusted to pH 3.0 (30:70, 
v=v). λ = 332 nm 
15–75 
ng/band 
 
6.91 
ng/band 
13.81 
ng/band 
Dosage forms and in 
human plasma 
41 
HPLC-UV Mobile phase acetonitrile: methanol: water: (10:55:35 v/v, 
pH 2.65±0.02), on a Nuclosil 100-10 C-18 (250×4.6mm), 
10 μ column. λ = 240 nm. Flow rate 1 ml-1 
5–100 μg 
ml-1 
0.0328 μg 
ml-1 
0.0994 
μg ml-1 
Bulk and dosage 
form 
42 
HPLC-F Column: A Purospher® RP-18 (125mm × 4mm i.d., 5 
μm). Mobile phase: 70.0 ml of methanol, 1.0 ml of acetic 
acid 99.8%, 0.02 ml of triethylamine, and 30.0 ml of 
distilled water, pH 3.83. λex = 244 nm (λem ≥ 389 nm) 
0.02–2.43 
mg l−1 
0.007 mg 
l−1 
- dissolution studies 
and quality control 
43 
HPLC-F μBondapak C-18 (3.9×300mm), 10 μ. Mobile phase: 
Water:ACN: Triethylamine (75:25:0.1). Flow rate 1.5 
ml/min. λex = 250 nm, λem = 370 nm. 
0.5-50 
ng/ml 
0.1 ng/ml 0.5 ng/ml Pharmacokinetics 44 
HPLC-UV Spherisorb RP-C-18 column (250mm×4.6mm id,  
5 μm) using water/acetonitrile/methanol/glacial acetic 
acid/diethylamine (25:35:40:1:0.017). flow rate 
1 ml min−1.  λ = 254 nm 
50–500 
μgml−1 
- - Stability Indicating 
method 
45 
HPLC-UV Kromasil C18 column (250 × 4.6 mm, 5.0 μm). Mobile 
phase A: ACN–diethylamine (0.05 ml), B: methanol, and 
C: 10 mM Ammonium acetate 
2–500 
μg/ml 
0.033 
μg/ml 
0.102 
μg/ml 
Stability Indicating 
method 
46 
HPLC-UV Kromacil C18 column. Methanol mobile phase. Flow rate 
1.1 ml/min 
10-60 
μg/ml 
0.511 
μg/ml 
1.549 
μg/ml 
In tablets 47 
HPLC-UV Waters Spherisorb ODS2 column (250 mm×/4.6 mm i.d, 5 
μm) acetonitrile:water:acetic acid:diethyl amine 
(65:35:1:0.2). Flow rate 1 ml min-1. λ = 254 nm 
- - - Stress degradation 
studies 
48 
HPLC-UV IBM Cyano, 5μ spherical particles, 4.5 mm (id) × 250 mm, 
650 ml. Mobile phase: 0.05M monobasic sodiun phosphate 
solution and 350 ml acetonitrile pH was adjusted to 3.0 
with phosphoric acid. λ = 268 m for PRZ and 254 for 
impurities. 
50-1250 
ng/ml 
0.6 ng/ml - Stability indicating 
assay for each drug 
substance and its 
impurities. 
(Prazosin and 
polythiazide 
combination) 
49 
HPLC-F Stainless-steel tube (250 × 5 mm I.D.) packed with 
Spherisorb S5W silica (5 μm). Mobile phase 10 mM 
ammonium perchlorate in methanol adjusted to pH 6.7 by 
the addition of 1 ml/l methanolic sodium hydroxide (0.1 
M), flow-rate of 2.0 ml/min. λex 250 nm, λem 370--700 nm. 
2-300 
μg/L 
1 μg/L - Prazosin and 
terazosin in 
biological fluids 
50 
HPTLC Silica gel aluminum plates 60F254 (20 × 15 cm, 200 μm 
thickness) mobile phase composed of methylene 
chloride:n-hexane:methanol 
(8.8:0.3:0.9, by volume). λ = 254 nm 
200–2000 
ng/spot 
4.62 
ng/spot 
14.00 
ng/spot 
Formulations 51 
HPLC-UV Cyano column (150 x 4.6 mm), mobile phase: acetonitrile: 
methanol: water (45:5:50% v/v) and 3 mM heptane 
sulphonic acid sodium. λ = 230 nm. Flow rate was 1-5 
ml/min. 
0.5-7 
μg/ml 
0.05 
μg/ml 
- Formulations 52 
HPTLC 60F–254 plates, [20 × 10 cm with 250 μm thickness 
Mobile phase: chloroform and methanol in the ratio 
9.5:0.5. 
0.8-1.2 
mg/ml 
0.017 
mg/ml 
0.053 
mg/ml 
Separation with 
other alpha blockers 
53 
HPLC-UV Kromasil C18 column (250 × 4.6 mm, 5.0 μm), a UV 
detector at 230 nm and a elution was performed under a 
gradient mobile phase composed of (A) ACN diethylamine 
(0.05 mL), (B) methanol, (C) 10 mM ammonium acetate 
and (D) Water. Flow rate: 1 ml/min 
4-16 μg/ml 0.1 μg/ml 0.33 
μg/ml 
 
Table 3: Summary of different chromatography methods 
Principle Dosage form Method Limit Ref 
HPLC-UV Prazosin tablet Chromatography condition: Column (200×4 mm, 5μm), Zorbax Sil, Mobile phase: 
(0.01% diethylamine in glacial acetic acid, water and methanol in 2:2:96 ratio. 
Dilutions prepared in glacial acetic acid, water and methanol in 2:2:96 ratio. Flow 
rate 1 ml/min, λ = 254 nm. 
90-110 % of stated 
amount 
54 
HPLC-UV Prazosin tablet Chromatography condition: Column (200×4 mm, 5μm), Mobile phase: (0.01% 
diethylamine in glacial acetic acid, water and methanol in 2:2:96 ratio. Dilutions 
prepared in glacial acetic acid, water and methanol in 2:2:96 ratio. Flow rate 1 
ml/min, λ = 254 nm. 
Not less than 98.5% and 
not more than 101.0 % 
55 
 
Potentiometry Prazosin HCl 0.35 gm in 20 ml formic acid and 30 ml acetic anhydride. Titrate with 0.1 M 
perchloric acid. 
Not less than 90.0% and 
not more than 110.0% 
HPLC-UV Prazosin HCl Chromatography condition: Column (250×4.6 mm, 5μm), Mobile phase: 
methanol, water, acetic acid and diethylamine (3500: 1500: 50:1). Flow rate is 
adjusted to RT 8 min, λ = 254 nm. 
Not less than 97.0% and 
not more than 103.0% 
56 
HPLC-UV Prazosin HCl Chromatography condition: 4.6-mm × 25-cm column contains packing L3. Mobile 
phase: mixture of 700 ml of methanol, 300 ml of water, 10 ml of glacial acetic acid 
and diethylamine 0.2 ml. Dilutions prepared in methanol water mixture in ratio 
(7:3). Flow rate adjusted to RT between 6 and 10 minutes, λ = 254 nm. 
Not less than 97.0 % and 
not more than 103.0 % 
57 
 
HPLC-UV Prazosin HCl 
capsules 
Mobile phase, Chromatographic system, and Procedure are sme as Prazosin HCl. 
Dilutions are prepared in Acid–methanol solution (300 ml water+0.85 ml HCl and 
diluted to 1000 ml with methanol). 
Not less than 
90.0 % and not more 
than 110.0 % of the 
labeled amount 
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2.3 Other methods 
Modern electrochemical methods are now 
sensitive, selective, rapid and easy techniques applicable to 
analysis in the pharmaceu-tical fields, and indeed in most 
areas of analytical chemistry. They are probably the most 
versatile of all trace pharmaceutically active compound 
analysis [58,59]. Some methods based on electroanalytical 
techniques are also available including potentiometry, 
amperometry, voltametry, capillary electrophoresis and 
electrochemical sensors. All of these reported methods are 
described in Table 4. 
 
Table 4: Summary of some electroanalytical methods reported in literature 
Principle Method 
Linear 
range 
LOD LOQ Application Ref 
Potentiometric Plastic membrane electrode based on incorporation of 
an ion pair complex of phosphotungstate (PT) anion 
with prazosinium cation in a poly (vinylchloride) 
(PVC) matrix plasticized with dioctylphthalate (DOP) 
2.7× 
10-6 to10-2 M 
2×10-6 to 
1×10-5 mol 
dm-3. 
- Solution and 
tablets 
60 
Potentiometric PVC-
membrane sensor 
Electrode made up of liquid plasticized PVC and was 
based on a water-insoluble Prazosin–tetraphenyl borate 
ion-pair complex as 
an ion-exchanger. 
1×10-5 and 
1×10-2 mol 
L-1 
6.3×10-6 
mol L-1 
- Tablets 61 
Flow 
injection analy sis with 
multiple-pulse amperometric 
(FIA-MPA) detection 
Boron-doped diamond film electrode. 2 to 200 
μmol L−1 
0.5 μmol 
L−1 
- Tablets 62 
Capillary electrophoresis Capillaries (50 and 75 μm I.D., 200 pm O.D., 64 cm 
long with 48 cm effective length) UV absorbance 
detector set at 220 nm. 
0.5-30 μg/ml - - human urine 63 
Capillary electrophoresis 50 cm×75 μm i.d. capillary using a buffer containing 
20% acetonitrile, 60 mM ammonium acetate, and 1.0% 
glacial acetic in methanol medium, with applied 
voltage and capillary temperature of 23 kV and 25 °C, 
respectively. λ = 220 nm. 
5.0–250 μg 
mL−1 
0.5 μg 
mL−1 
- Tablets 64 
Differential pulse 
voltammetry (DPV) 
Three-electrode system was used: a platinum counter, 
an Ag:AgCl reference and a nafion modified carbon 
paste electrode (NMCPE) as working electrode. 
4.0×10-11 to 
4.0×10-8 M 
3.1×10-11 
M 
- Urine and 
tablets 
15 
Electrochemical sensor 
based on in situ modification 
of graphite electrode via 
graphene 
nanosheets (GNs) 
Adsorptive stripping differential pulse voltammetry 
(Ads-DPV) 
0.09–100 
mM 
0.02 mM - In urine 
samples and 
tablets 
65 
 
3. Conclusion 
Hypertension is one of the most serious diseases 
of the XXI century concerning about 20 to 30% of the 
world population of adults [66]. Prazosin is largely free of 
toxic or major symptomatic side effects, with the exception 
of postural hypotension and syncope after first doses or 
large dose increments [67]. This review highlights the 
various analytical methods for the determination of 
prazosin in different matrices. The spectrophotometry, 
chromatography, pharmacopoeial and electroanalytical 
methods were presented in a systematic way in Table 1, 2, 
3 and 4 respectively. This review is helpful for the 
scientists engaged in the study of Prazosin. 
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